Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages

  Younossi, Zobair M ^a,b   Stepanova, Maria ^a,b   Henry, Linda ^b   Gane, Edward ^c   Jacobson, Ira M ^d   Lawitz, Eric ^e   Nelson, David ^f   Gerber, Lynn ^a,b   Nader, Fatema ^a   Hunt, Sharon ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

CLDQ HCV; FACIT F; Hepatitis C; Liver Disease; Quality of Life; WPAI

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; INTERFERON; URIDINE PHOSPHATE;

ABSENTEEISM; ADULT; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG EFFECT; EMPLOYMENT STATUS; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; QUESTIONNAIRE; SEX DIFFERENCE; TREATMENT DURATION; WORK CAPACITY; WORK PRODUCTIVITY; CHRONIC LIVER DISEASE QUESTIONNAIRE HCV VERSION; CLINICAL ASSESSMENT TOOL; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE AND WORK PRODUCTIVITY AND ACTIVITY INDEX; GENOTYPE; PRODUCTIVITY; QUALITY OF LIFE INDEX; TREATMENT OUTCOME; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; CLASSIFICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; EFFICIENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84904381202     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.11.032     Document Type: Article

References (43)

1. Vietri J., Prajapati G., El Khoury A.C. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterology 2013, 13:16.
2. Ward J.W. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med 2013, 21:15-19.
3. Younossi Z.M., Zheng L., Stepanova M., et al. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther 2013, 37:703-709.
4. Foster G.R., Goldin R.D., Thomas H.C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998, 27:209-212.
5. Ware J.E., Bayliss M.S., Mannocchia M., et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response-the Interventional Therapy Group. Hepatology 1999, 30:550-555.
6. Marcellin F., Preau M., Ravaux I., et al. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007, 8:320-327.
7. Racciatti D., Gorgoretti V., Sepede G., et al. An Italian study on health related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences. Int J Immunopathol Pharmacol 2011, 24:673-681.
8. Ashrafi M., Modabbernia A., Dalir M., et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. JPsychosom Res 2012, 73:218-224.
9. Davis G.L., Balert L.A., Schiff E.R., et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994, 16:334-343.
10. Kallman J., O'Neill M.M., Larive B., et al. Fatigue and health related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007, 52:2531-2539.
11. Foster G.R. Quality of life consideration for patients with chronic hepatitis C. JViral Hepat 2009, 16:605-611.
12. Svirlith N., Pavic S., Terzic D., et al. Reduced quality of life in patients with chronic viral liver disease as assessed by the SF-12 questionnaire. JGastrointest Liver Dis 2008, 17:405-409.
13. John-Baptiste A.A., Tomlinson G., Hsu P.C., et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009, 104:2439-2448.
14. Kamal S.M., Ahmed A., Mahmoud S., et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4: a randomized trial and quality of life analysis. Liver Int 2011, 31:401-411.
15. McHutchison J.G., Ware J.E., Bayliss M.S., et al. The effects of interferon alpha 2-b in combination with ribavirin and health related quality of life and productivity. JHepatol 2001, 34:140-147.
16. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4:353-365.
17. Younossi Z.M., Guyattc G., Kiwia M., et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45:295-300.
18. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. JClin Oncol 1993, 11:570-579.
19. Webster K., Odom L., Peterman A., et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Quality of Life Research 1999, 8:604.
20. Bezemer G., van Gool A.R., Verjeij-Hart E., et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life: an international, multicenter, randomized, controlled study. BMC Gastroenterology 2012, 12:11.
21. Hassanein T., Cooksley G., Sulkowski M., et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. JHepatol 2004, 40:675-681.
22. Bernstein D., Kleinman L., Barker C.M., et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35:704-708.
23. A special meeting review edition: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013-the 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013. Gastroenterol Hepatol (N Y) 2013;9(Suppl 3):1-18.
24. Asselah T. Sofosbuvir-based interferon-free therapy for patients with HCV infection. JHepatol 2013, 59:1342-1345.
25. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEngl J Med 2013, 368:1867-1877.
26. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEngl J Med 2013, 368:1878-1887.
27. Younossi Z.M., Stepanova M., Mir H.M., et al. Minimal impact of sofosbuvir+ribavirin on health related quality of life (HRQL) compared to pegylated interferon+ribavirin for chronic hepatitis C (CH-C): results from fission+positron studies. J Hepatol 2014, 60:741-747.
28. Escorpizo R., Bombardier C., Boonen A., et al. Worker productivity outcome measures in arthritis. JRheumatol 2007, 34:1372-1380.
29. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003, 1:79.
30. Binion D.G., Louis E., Oldenburg B., et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011, 25:492-496.
31. Pockros P.J., Shiffman M.L., Schiff E.R., et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004, 40:1450-1458.
32. Crone C., Gabriel G.M. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. JPsychiatr Pract 2003, 9:93-110.
33. Dan A.A., Martin L.M., Crone C., et al. Depression, anemia and health-related quality of life in chronic hepatitis C. JHepatol 2006, 44:491.
34. Younossi Z., Kallman J., Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007, 45:806-816.
35. Davis M.P., Walsh D. Mechanisms of fatigue. JSupport Oncol 2010, 8:164-174.
36. Michel L., Villes V., Dabis F., et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co infected patients: ANRS Co13 Hepavih, France, 2006-2008. JViral Hepat 2010, 17:650-660.
37. Raedler T.J. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011, 24:519-525.
38. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
39. You H., Lu W., Zhao S., et al. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother 2013, 14:1467-1476.
40. Sockalingam S., Blank D., Al Jarad A., et al. Acomparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics 2011, 52:433-440.
41. Pattullo V., McAndrews M.P., Damyanovich A., et al. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Intl 2011, 31:1028-1038.
42. Sockalingam S., Blank D., Al Jarad A., et al. The role of attachment style and depression in patients with hepatitis C. JClin Psychol Med Settings 2013, 20:227-233.
43. Spiegel B., Younossi Z., Hays R.D., et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800.